

**IN THE CLAIMS:**

1. (Cancelled)
2. (Cancelled)
3. (Currently Amended) The siNA molecule of claim ~~[[1]]~~ 37, wherein said siNA molecule comprises one or more ribonucleotides.
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Cancelled)
10. (Cancelled)
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Cancelled)
15. (Cancelled)
16. (Currently Amended) The siNA molecule of claim ~~[[9]]~~ 37, wherein the ~~fragment comprising said sense region~~ first strand includes a terminal cap moiety at the 5'-end, the 3'-end, or both of the 5' and 3' ends of the ~~fragment comprising said sense region~~ first strand.

17. (Original) The siNA molecule of claim 16, wherein said terminal cap moiety is an inverted deoxy abasic moiety.
18. (Cancelled)
19. (Cancelled)
20. (Cancelled)
21. (Currently Amended) The siNA molecule of claim ~~[[18]]~~ 37, wherein said ~~antisense~~ siNA comprises ~~[[a]]~~ one or more phosphorothioate internucleotide ~~linkage at the 3' end of said antisense region~~ linkages.
22. (Cancelled)
23. (Currently Amended) The siNA molecule of claim ~~[[9]]~~ 37, wherein each of the two ~~fragments~~ strands of said siNA molecule comprise 21 nucleotides.
24. (Currently Amended) The siNA molecule of claim 23, wherein about 19 nucleotides of each strand ~~fragment~~ of the siNA molecule are base-paired to the complementary nucleotides of the other strand ~~fragment~~ of the siNA molecule and wherein at least two 3' terminal nucleotides of each strand ~~fragment~~ of the siNA molecule are not base-paired to the nucleotides of the other strand ~~fragment~~ of the siNA molecule.
25. (Cancelled)
26. (Cancelled)
27. (Currently Amended) The siNA molecule of claim ~~[[23]]~~ 37, wherein ~~all 21 nucleotides of each fragment~~ the first strand and the second strand of the siNA molecule are ~~base-paired to the perfectly~~ complementary nucleotides of the other fragment of the siNA molecule.
28. (Cancelled)
29. (Cancelled)

30. (Currently Amended) The siNA molecule of claim [[9]] 37, wherein the 5'-end of ~~the fragment comprising said antisense region~~ second strand optionally includes a phosphate group.
31. (Cancelled)
32. (Cancelled)
33. (Currently Amended) A pharmaceutical composition comprising the siNA molecule of claim [[1]] 37 in an acceptable carrier or diluent.
34. (Cancelled)
35. (Cancelled)
36. (Cancelled)
37. (New) A chemically synthesized double stranded short interfering nucleic acid (siNA) molecule consisting essentially of a first nucleic acid strand and a second nucleic acid strand, wherein
- a. the first strand has complementarity to the second strand;
  - b. the second strand has 18-24 nucleotides complementary to a human synuclein-1 (SNCA) RNA comprising SEQ ID NO:311;
  - c. the siNA molecule has at least one sugar modification.
38. (New) The siNA molecule of claim 37, wherein said sugar modification comprises a 2'-O-methyl nucleotide modification.
39. (New) The siNA molecule of claim 37, wherein said sugar modification comprises a 2'-deoxy-2'-fluoro nucleotide modification.
40. (New) The siNA molecule of claim 37, wherein said sugar modification comprises a 2'-deoxy nucleotide modification.